MML Investors Services
SAGE

MML Investors Services’s Sage Therapeutics SAGE Stock Holding History

MML Investors Services’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,103
Closed -$202K – 1589
2019
Q2 		$202K Buy
+1,103
New +$188K ﹤0.01% 1508

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

MML Investors Services's SAGE Position: Q3 2019 in Review

MML Investors Services sold out of Sage Therapeutics (SAGE) in Q3 2019, closing a stake of 1,103 shares — an estimated $202K sold.

MML Investors Services first reported a position in SAGE in Q2 2019 and held it in 1 quarter. The position peaked at $202K in Q2 2019. 284 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

  • MML Investors Services reported no remaining Sage Therapeutics position as of Q3 2019 after selling out during the quarter.
  • MML Investors Services sold 1,103 Sage Therapeutics shares in Q3 2019, an estimated $202K.
  • MML Investors Services first reported a position in Sage Therapeutics in Q2 2019 and held it in 1 quarter.
  • MML Investors Services's Sage Therapeutics position peaked at $202K in Q2 2019.
  • 284 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on MML Investors Services's 13F filing for Q3 2019, filed 14 Nov 2019.